Paratek Pharmaceuticals Competitors and Similar CompaniesClear all
Paratek Pharmaceuticals's competitors and similar companies include Paradigm Diagnostics, QGel, Cipla and Keros Therapeutics.
 Paratek Pharmaceuticals Paratek Pharmaceuticals is focused on the discovery, development, and commercialization of medicines designed to save lives and alleviate suffering. |  Paradigm Diagnostics Paradigm Diagnostics is a precision medicine company focused on comprehensive cancer testing. |  QGel QGel synthetic extracellular matrices mimic the complex physiology of the human body to bring predictability & efficiency to drug discovery & diagnostics. |  Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products. |  Keros Therapeutics Keros Therapeutics is a biotechnology company that develops therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta. | |
Founding Date | Founding Date 1996 | Founding Date 2012 | Founding Date 2009 | Founding Date 1935 | Founding Date 2015 |
Type | Type Public | Type Private | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Boston, US HQ King Of Prussia, US | Locations Phoenix, US HQ | Locations Lausanne, CH HQ | Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more | Locations Lexington, US HQ South Wharf, AU |
Employees | Employees 10123% increase | Employees 717% increase | Employees 147% decrease | Employees 27,764 | Employees 7854% decrease |
Valuation ($) | Valuation ($) 127.8 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 2.3 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $160.3m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) ₹277.1b (FY, 2026) | Revenue (est.) $244.1m (FY, 2025) |
Cost of goods | Cost of goods $23.1m (FY, 2022) | Cost of goods N/A | Cost of goods N/A | Cost of goods ₹95.5b (FY, 2026) | Cost of goods N/A |
Gross profit | Gross profit $137.2m (FY, 2022) | Gross profit N/A | Gross profit N/A | Gross profit ₹195b (FY, 2026) | Gross profit N/A |
Net income | Net income ($63.6m) (FY, 2022) | Net income N/A | Net income N/A | Net income ₹38.7b (FY, 2026) | Net income $87m (FY, 2025) |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round $ 15m (almost 7 years ago) | Latest funding round $ 12m (over 9 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 93m | Total funding raised $ 23.9m | Total funding raised $ 12m | Total funding raised N/A | Total funding raised $ 90m |
For sources of this data, please see the company profile
View Company Profiles
Paradigm Diagnostics
HQ
Phoenix, US
Employees
7↑ 17% increase
Paradigm Diagnostics is a precision medicine company focused on comprehensive cancer testing.
View companyQGel
HQ
Lausanne, CH
Employees
14↓ 7% decrease
QGel synthetic extracellular matrices mimic the complex physiology of the human body to bring predictability & efficiency to drug discovery & diagnostics.
View companyCipla
HQ
Mumbai, IN
Employees
27,764
Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
View companyKeros Therapeutics
HQ
Lexington, US
Employees
78
Keros Therapeutics is a biotechnology company that develops therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta.
View company